Published in Int J Cancer on August 22, 1997
Cross-platform comparison and visualisation of gene expression data using co-inertia analysis. BMC Bioinformatics (2003) 1.93
S100 proteins in cancer. Nat Rev Cancer (2015) 1.35
Identification of human epidermal differentiation complex (EDC)-encoded genes by subtractive hybridization of entire YACs to a gridded keratinocyte cDNA library. Genome Res (2001) 1.16
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis (2010) 1.11
Divalent metal ion complexes of S100B in the absence and presence of pentamidine. J Mol Biol (2008) 1.09
Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol (2003) 1.06
Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer (2000) 1.06
The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem (2010) 1.04
Expression of calcium-binding protein S100A2 in breast lesions. Br J Cancer (2000) 1.01
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer (2009) 1.01
Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol (2008) 1.00
CacyBP/SIP expression is involved in the clinical progression of breast cancer. World J Surg (2010) 0.99
S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer (2004) 0.97
Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. Nat Commun (2015) 0.96
S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am J Pathol (2010) 0.95
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
Calcium-binding S100 protein expression in pterygium. Mol Vis (2009) 0.95
Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res (2008) 0.92
S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res (2008) 0.91
Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas. Br J Cancer (1998) 0.91
Expression and clinical significance of S100A2 and p63 in esophageal carcinoma. World J Gastroenterol (2009) 0.90
Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. Biochemistry (2009) 0.89
Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(2+)-binding proteins S100A6 and S100A11. PLoS One (2008) 0.87
S100A13 is a new angiogenic marker in human melanoma. Mod Pathol (2010) 0.86
Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma. PLoS One (2013) 0.83
Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol (2006) 0.81
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS One (2013) 0.81
Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of A375 melanoma cells. J Cell Mol Med (2016) 0.80
Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells. J Mol Endocrinol (2010) 0.80
Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma. Korean J Urol (2010) 0.79
Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients. J Transl Med (2015) 0.79
Inhibition of protein-protein interactions with low molecular weight compounds. Curr Trends Med Chem (2008) 0.77
The association between S100A13 and HMGA1 in the modulation of thyroid cancer proliferation and invasion. J Transl Med (2016) 0.77
New Perspectives of "omics" Applications in Melanoma Research. Open Biochem J (2011) 0.77
Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Res (2009) 0.76
Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma. Onco Targets Ther (2012) 0.75
Upregulated expression of calcyclin-binding protein/siah-1 interacting protein in malignant melanoma. Ann Dermatol (2014) 0.75
A literature network of human genes for high-throughput analysis of gene expression. Nat Genet (2001) 13.88
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res (1993) 3.59
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11
Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes. Mutat Res (1988) 2.94
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78
Associations between gene expressions in breast cancer and patient survival. Hum Genet (2002) 2.67
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res (1996) 2.65
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene (2009) 2.49
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells. Eur J Immunol (1972) 2.34
Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst (1994) 2.25
Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst (1999) 2.21
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res (1997) 2.17
The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell (1974) 2.12
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst (1994) 2.06
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene (2009) 1.85
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. J Immunol (1971) 1.80
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol (1992) 1.68
S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res (1999) 1.67
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol (1992) 1.66
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66
A cancer therapy resistant to resistance. Nature (1997) 1.65
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58
Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res (1994) 1.58
Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res (1999) 1.57
Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res (1999) 1.56
Screening for germ line TP53 mutations in breast cancer patients. Cancer Res (1992) 1.55
Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol (1988) 1.54
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst (1990) 1.53
Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer (1997) 1.53
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res (2000) 1.42
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res (1988) 1.36
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res (1996) 1.35
Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum. Cell Immunol (1974) 1.35
Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol (1983) 1.32
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res (1997) 1.30
Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas. Oncogene Res (1989) 1.30
Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer (1999) 1.30
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer Res (2000) 1.27
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27
HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene (1997) 1.25
Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer (1978) 1.24
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res (2000) 1.24
Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J (2001) 1.23
Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer (1996) 1.22
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res (1992) 1.21
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20
Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Curr Biol (1998) 1.20
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ (1993) 1.20
Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol (1995) 1.20
Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (1996) 1.20
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res (1998) 1.20
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity. Int J Cancer (1980) 1.19
Cell adhesion and drug resistance in cancer. Curr Opin Oncol (1997) 1.18
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17
Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects. Cancer Res (1984) 1.15
Growth of precultured human glioma specimens in nude rat brain. J Neurosurg (1999) 1.15
Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J Cancer (1996) 1.15
Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer (1975) 1.14
Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer (1995) 1.14
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene (2000) 1.12
Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol (1993) 1.12
Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat (1995) 1.12
An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst (1976) 1.11
Toxicity, distribution and elimination of the cancerostatic lectins abrin and ricin after parenteral injection into mice. Br J Cancer (1976) 1.11
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10
Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer (1995) 1.10
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer (1999) 1.10
Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. Cancer Res (1988) 1.10
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas. Br J Cancer (1981) 1.10
Adhesion-dependent multicellular drug resistance. Anticancer Drug Des (1999) 1.09
Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A (1990) 1.09
TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene (1996) 1.09